NCT02239354View on ClinicalTrials.gov

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Type 1 Diabetes Mellitus
Interventions
COMBINATION_PRODUCT

VC-01™ Combination Product

Biologic and Device

Trial Locations (2)

Unknown

University of California at San Diego, San Diego

T6G 2B7

University of Alberta Hospital, Edmonton

Sponsors

Lead Sponsor

ViaCyte
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

ViaCyte

INDUSTRY

NCT02239354 - A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus | Biotech Hunter | Biotech Hunter